REG - AstraZeneca PLC - Acquisition of TeneoTwo completed

AstraZenecaAnnouncement

11/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220811:nRSK6383Va&default-theme=true

RNS Number : 6383V  AstraZeneca PLC  11 August 2022

11 August 2022 07:00 BST

 

Acquisition of TeneoTwo for its clinical-stage

T-cell engager completed

 

AstraZeneca has completed the acquisition of TeneoTwo, Inc
(https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html)
. (TeneoTwo)(i), including its Phase I clinical-stage CD19/CD3 T-cell engager,
TNB-486, currently under evaluation in relapsed and refractory B-cell
non-Hodgkin lymphoma.(1) AstraZeneca will develop TNB-486 as a potential new
medicine for B-cell haematologic malignancies.

 

Financial considerations

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an
upfront payment of $100m. Under the terms of the agreement, AstraZeneca will
make additional contingent R&D-related milestone payments of up to $805m
and additional contingent commercial-related milestone payments of up to $360m
to TeneoTwo's former equity holders.

 

This acquisition did not include the transfer of people or facilities.

 

(i)TeneoTwo, Inc., is a majority owned subsidiary company of TBio, LLC, a
limited liability company formed in Delaware, US

 

Notes

 

AstraZeneca in haematology

AstraZeneca is pushing the boundaries of science to redefine care in
haematology. We have expanded our commitment to patients with haematologic
conditions, not only in oncology but also in rare diseases with the
acquisition of Alexion, allowing us to reach more patients with high unmet
needs. By applying our deep understanding of blood cancers, leveraging our
strength in solid tumour oncology and delivering on Alexion's pioneering
legacy in complement science to provide transformative medicines for rare
diseases, we are pursuing the end-to-end development of novel therapies
designed to target underlying drivers of disease.

 

By targeting haematological conditions with high unmet medical needs, we aim
to deliver innovative medicines and approaches to improve patient outcomes.
Our goal is to help transform the lives of patients living with malignant,
rare and other related haematologic diseases, shaped by insights from
patients, caregivers and physicians to have the most meaningful impact.

 

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.   Clinicaltrials.gov. A Study of TNB-486 in Subjects With Relapsed or
Refractory B-Cell Non-Hodgkin Lymphoma. Available at
https://clinicaltrials.gov/ct2/show/NCT04594642
(https://clinicaltrials.gov/ct2/show/NCT04594642) . Accessed 2 August 2022.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQEADPEFDAAEAA